NeutralLOW severityEarnings8d ago

Claritev expects at least $1.1B 2027 revenue, raises 2026 outlook to $1.038B-$1.043B on NSA momentum

Claritev expects at least $1.1B 2027 revenue, raises 2026 outlook to $1.038B-$1.043B on NSA momentum — $CTEV one-month chart
$CTEV daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOK’s read

$CTEV surged 3.96% to $23.61, near its 52-week low, after raising its 2026 revenue outlook and signaling NSA momentum. Earnings are due today, adding a key data point for investors watching the Health Care sector, which is currently calm.

Written by Wook AI Nov 9, 2:25 PM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about CTEV. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · claritevEvent risk Low

Nothing reported about claritev across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 111% a year
Now $22.92Week $19.34–$26.50 (±15.6%)Month $15.58–$30.26 (±32.0%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: The headline hinges on a single figure — $1.1B — but the real story lies in how that number stacks up against what investors expected.
  • How the stock is trading: $CTEV -8.28% in the latest session.
  • Timing: It came out during market hours, so traders could react the same day, and the session move may reflect that.
Amount$1.1 billion
Amount$1.038 billion
Amount$1.043 billion

Where the stock stands

Claritev ($CTEV) dropped 8.28% to $22.92 in the latest session. Over the past month it is up 4.4%. It now sits 59% under the 52-week high of $55.50 and 99% above the year's low of $11.50. The year's high was 4.8 times its low, which makes double-digit swings fairly routine here.

What the filings say

In its latest report (10-Q, filed Nov 9, 2026), $CTEV lost $61.8M over the quarter to Sep 30, 2026 on revenue of $268.3M (+4.2% QoQ). Operations brought in $65.0M of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was negative at $64.2M. It carried $4.66B of debt against $10.1M of cash on Sep 30, 2026 — net debt of $4.65B. Liabilities of $5.02B exceeded assets of $4.68B on Sep 30, 2026, leaving book equity negative. The company filed an 8-K — the form for material events — on Nov 9, the same day as this story; it is $CTEV's own account and the first thing to read. Figures are as filed with the SEC; the $CTEV page has the full statements.

How much coverage it is getting

This is one of 2 stories on Claritev in Wook's last 30 days of coverage, including 0 this week. None came this week, so coverage has gone quiet. Going by their wording, 0 read bullish, 2 neutral and 0 bearish. This one reads neutral too, in line with most of them. Seeking Alpha wrote 2 of them; the rest came from other outlets.

The bigger picture

Earnings reports are less about the numbers and more about how they stack up against expectations — and how the guidance shapes the narrative. Wook's supply-chain scanner shows no unusual stress in Health Care today.

What to watch next

The $CTEV page has the full chart, filings, and valuation model. Comparing coverage from different outlets is the fastest way to see if the story is confirmed or just repeated. Wook AI can pull live data and run the numbers on request.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Seeking Alpha published this on November 9, 2026. $CTEV has moved -8.47% ($25.04 to $22.92). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy